Prescription opioid use disorder: A complex clinical challenge
Understanding patients’ aberrant medication-taking behaviors can greatly aid treatment
Related Resources
- Ries RK, Fiellin D, Miller SC, et al, eds. Principles of addiction medicine. 4th ed. Hagerstown, MD: Lippincott Williams & Wilkins; 2009.
- Department of Veterans Affairs. Department of Defense. VA/DoD clinical practice guideline for management of opioid therapy for chronic pain. Appendix C: sample opioid pain care agreement. https://www.healthquality.va.gov/COT_312_Full-er.pdf. Published May 2010. Accessed June 21, 2012.
- Weaver M, Schnoll S. Addiction issues in prescribing opioids for chronic non-malignant pain. J Addiction Med. 2007;1(1):2-10.
- Weaver M, Heit HA, Savage S, et al. Clinical case discussion: chronic pain management. J Addiction Med. 2007;1(1):11-14.
Drug Brand Names
- Buprenorphine • Subutex
- Buprenorphine/naloxone • Suboxone
- Codeine • Tylenol with codeine, others
- Fentanyl • Duragesic, Actiq
- Hydrocodone • Lortab, Vicodin, others
- Methadone • Dolophine, Methadose
- Morphine • Roxanol
- Naltrexone extended-release • Vivitrol
- Oxycodone • OxyContin, Roxicodone
Disclosures
The authors report no financial relationship with any company whose products are mentioned in this article or with manufacturers of competing products.
Dr. Frankowski’s time toward this project was provided by the American Board of Addiction Medicine-accredited Cincinnati VA Addiction Medicine Research Fellowship, affiliated with the CeTREAD, Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati, Cincinnati, OH.
The statements in this publication do not necessarily reflect the views or opinions of the Department of Veterans Affairs.
Acknowledgement
The authors thank Catherine Constance and Sandra Mason at the Cincinnati VA Medical Center for their administrative assistance.
